According to Nova one advisor, the US Therapeutic Plasma Exchange market was valued at USD 201.2 million in 2021 and it is expected to hit around USD 350.4 million by 2030 with a CAGR of 9.2% during the forecast period 2022 to 2030.
According to Nova one advisor, the US Therapeutic Plasma Exchange market was valued at USD 201.2 million in 2021 and it is expected to hit around USD 350.4 million by 2030 with a CAGR of 9.2% during the forecast period 2022 to 2030.
Full Report is Ready | Download Free Sample@ https://www.novaoneadvisor.com/report/sample/6855
Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements. However, factors such as the high cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model are expected to restrain the growth of this market to a certain extent during the forecast period.
Covid-19 Impact on the US Therapeutic Plasma Exchange Market
Convalescent plasma therapy has been successful in treating infected patients with coronavirus. Antivirals, convalescent plasma, and biologics have been used with mixed results. The profound “cytokine storm” induced endotheliopathy and microthrombotic disease in patients with COVID-19 leads to acute respiratory distress syndrome, sepsis, and multi-organ failure. Therapeutic plasma exchange (TPE) is the only procedure known to directly and rapidly decrease plasma viscosity, suggesting that TPE may improve patient outcomes in critically ill patients with COVID-19 by decreasing plasma viscosity and thereby enhancing blood flow.
Report Scope of the US Therapeutic Plasma Exchange Market
| Report Coverage | Details |
| Revenue Projection By 2030 | USD 350.4 million |
| Growth Rate | CAGR of 9.2% from 2022 to 2030 |
| Base Year | 2021 |
| Historical data | 2018 - 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product & Technology, Indication, End User |
| Companies Mentioned | Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Miltenyi Biotec (Germany), Medica S.p.A. (Italy), Medicap Clinic GmbH (Germany), and Infomed (Switzerland). |
US Therapeutic Plasma Exchange Market Dynamics
Driver: Technological advancement
Continuous-flow centrifugation technology is a high-precision approach that has been refined over the past decade. It brings innovations in patient comfort and more efficient processing of blood and plasma products. This technique requires minimal blood flow compared with other technologies, such as membrane separation approaches. It is an improved technology that allows easy access to blood through the patient’s peripheral veins (antecubital or brachial), as compared with other membrane-based apheresis devices that mostly require invasive central venous catheterization. These technical innovations also result in better patient comfort and safety during the TPE procedure (than was previously possible) and more accurate fluid balance control for better hemodynamic stability during treatment.
Restraint: High cost of devices
The cost of apheresis devices is a critical factor in determining the adoption of plasma exchange by healthcare providers and, ultimately, by patients. Apheresis devices are used by blood banks for blood component collection, while hospitals use these devices for therapeutic plasma exchange procedures. The high cost of apheresis devices and disposables also increases the overall cost of apheresis procedures. For instance, in the US, the cost of an apheresis procedure is ~USD 2,500 per treatment. Patients might not opt for these procedures owing to their high cost.
Opportunity: Therapeutic plasma exchange for pediatric patients
The growing adoption of therapeutic plasma exchange for the treatment of various diseases is expected to offer potential growth opportunities to market players in the coming years. Therapeutic plasma exchange (TPE) is used in the treatment of neurological, hematological, renal, and autoimmune diseases with known or suspected immune pathogenesis. The use of therapeutic plasma exchange procedures in pediatric patients is very low. This therapeutic modality presents several technical challenges in children but is increasingly being used in pediatric nephrology. Owing to advances in technology, TPE procedures are carried out in pediatric patients for renal diseases.
Challenge: Dearth of skilled professionals
Therapeutic plasma exchange procedures require skilled professionals and apheresis nurse specialists, as most of these procedures are performed using apheresis systems. However, globally, there is a shortage of these physicians and surgeons. As the demand for TPA has increased, so has the need for apheresis nurses with their expertise in clinical patient care, transfusion medicine, and technology. Apheresis nurses provide care to a diversified population ranging from healthy donors to acute or chronically ill patients while adhering to strict, ever-changing regulatory issues. During an apheresis procedure, the nurse manages the donor/patient’s clinical status, the venous access, the infusion of blood components or specialized fluids, and the apheresis device. Additional responsibilities include donor/patient/family/public education.
Consumables segment to witness the highest growth during the forecast period
Based on products, the US therapeutic plasma exchange market has been segmented into devices and consumables. The consumables segment witness the highest growth during the forecast period. The fastest growth of this segment can be attributed to the recurrent use of these products, the increasing number of therapeutic plasma exchange procedures, and favorable reimbursement policies for TPE procedures.
The centrifugation segment is expected to account for the largest share of the US therapeutic plasma exchange market in 2021
On the basis of technology, the US therapeutic plasma exchange market has been segmented into centrifugation and membrane separation. In 2021, the centrifugation technology segment accounted for
the largest share of the US therapeutic plasma exchange market. The large share of this segment can be attributed to the advantages offered by centrifugation over membrane separation, such as high efficiency and its ability to separate all types of blood components.
Neurological segment to witness the highest growth during the forecast period
On the basis of indication, the US therapeutic plasma exchange market has been segmented into neurological disorders, renal disorders, hematologic disorders, metabolic disorders, and other indications.
In 2021, the neurological disorders segment accounted for the largest share of the US therapeutic plasma exchange market. Growth in this market is majorly driven by the rising prevalence and incidence of neurological diseases in the geriatric population, increasing awareness about the treatment of neurological diseases using plasma exchange, and rising investments by key players for R&D on the new application areas of therapeutic plasma exchange in the treatment of neurological disorders.
The blood collection centers and blood component providers segment is expected to account for the largest share of the US therapeutic plasma exchange market in 2021
On the basis of end users, the US therapeutic plasma exchange market has been segmented into blood
collection centers and blood component providers, hospitals and transfusion centers, and other end users. In 2020, the blood collection centers and blood component providers segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this end-user segment is mainly attributed to the rising number of blood component donations, the growing number of blood centers, and the increasing number of therapeutic plasma exchange procedures and plasma donations due to COVID-19.
Recent Developments
- In April 2020, Terumo BCT and Marker Therapeutics received the first device FDA emergency use authorization (EUA) to treat acute respiratory failure in COVID-19 patients.
- In May 2020, cerus corporation received FDA regulatory approval for the manufacturing of INTERCEPT plasma with a new, alternative plastic disposable kit.
- In December 2020, Haemonetics corporation opened its new corporate headquarters in Downtown Boston.
- In February 2020, Fresenius Medical Care acquired NxStage Medical to widen its product portfolio in the areas of renal care and critical care.
- In April 2021, Fresenius collaborated with DaVita and other dialysis providers to support a broader kidney care community in the US.
Some of the prominent players in the US Therapeutic Plasma Exchange market include:
Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Miltenyi Biotec (Germany), Medica S.p.A. (Italy), Medicap Clinic GmbH (Germany), and Infomed (Switzerland).
Segments Covered in the Report
This report forecasts revenue growth at regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2018-2030. For this study, Nova one advisor has segmented US Therapeutic Plasma Exchange market based on services and region:
US Therapeutic Plasma Exchange Market, By Product & Technology
- By Product
- Consumables
- Devices
- By Technology
- Centrifugation
- Membrane Separation
US Therapeutic Plasma Exchange Market, By Indication
- Neurological Disorders
- Guillain–Barré syndrome
- Chronic inflammatory demyelinating polyneuropathy
- Myasthenia gravis
- Multiple sclerosis
- PANDASa
- Hematology Disorders
- Thrombotic thrombocytopenic purpura
- Atypical haemolytic uraemic syndrome
- Hyperviscosity syndromes
- Severe/symptomatic Cryoglobulinemia
- Renal Disorders
- Goodpasture’s syndrome
- Wegener’s glomerulonephritis
- Antibody-mediated renal transplant rejection
- Metabolic Disorders
- Familial hypercholesterolaemia (homozygous)
- Other Indications
US Therapeutic Plasma Exchange Market, By End User
- Blood Collection Centres & Blood Component Providers
- Hospitals & Transfusion Centres
- Other End Users
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the US Therapeutic Plasma Exchange industry analysis from 2022 to 2030 to identify the prevailing US Therapeutic Plasma Exchange industry opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the US Therapeutic Plasma Exchange industry segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the U.S. market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as US Therapeutic Plasma Exchange industry trends, key players, market segments, application areas, and market growth strategies.
For Purchase Inquiry @ https://www.novaoneadvisor.com/report/checkout/6855
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
Blog: https://qyresearchmedical.com/
About Us
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. We endeavor to give our clients latest insights on upcoming technologies, new developing markets, dynamically changing business conditions and most recent business-driven applications. These insights help our clients to take informed decisions for their business growth. We for the most part center around supporting our clients with aggressive insight, helping them to anchor an upper hand in the market and achieve reasonable development in various market spaces.